Skip navigation
Skip navigation

Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01

Tinker, AV; Gebski, V; Fitzharris, B; Buck, M; Stuart-Harris, Robin; Beale, Phillip; Goldrick, A; Rischin, D


Objective: To determine the response rate of weekly docetaxel in women with relapsed epithelial ovarian cancer previously treated with paclitaxel and at least one line of platinum-based chemotherapy. Methods: In this multi-center phase II trial, 37 patients with relapsed disease were enrolled and treated with weekly docetaxel at 35 mg/m for 5 out of 6 consecutive weeks. Two patient cohorts were considered, those who progressed or relapsed within 4 months (N = 7) or at greater than 4 months (N =...[Show more]

CollectionsANU Research Publications
Date published: 2007
Type: Journal article
Source: Gynecologic Oncology
DOI: 10.1016/j.ygyno.2006.10.006


File Description SizeFormat Image
01_Tinker_Phase_II_trial_of_weekly_2007.pdf262.71 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator